Cardiovascular magnetic resonance has revolutionised the diagnosis of cardiomyopathy, particularly through the use of late gadolinium enhancement imaging which provides the unique opportunity to assess myocardial fibrosis in vivo. More recently, the prognostic capability of cardiovascular magnetic resonance to predict outcomes has been assessed. Traditional risk markers do not at present adequately predict outcomes in either dilated cardiomyopathy or hypertrophic cardiomyopathy, which are the two most common causes of primary heart muscle disease. Many of these existing markers reflect underlying disease severity. Given the important role fibrosis is thought to play in the pathogenesis and sequelae of these cardiomyopathies, the presence and amount of fibrosis has been proposed as a potential novel risk factor for adverse events. This paper reviews the evidence for late gadolinium enhancement as a prognostic marker in dilated and hypertrophic cardiomyopathy and highlights the challenges ahead.
Cardiopulmonary Imaging, Section Head
Cleveland Clinic Florida
Latest posts by Jacobo Kirsch (see all)
- Coronary Computed Tomography Angiography Versus Radionuclide Myocardial Perfusion Imaging in Patients With Chest Pain Admitted to Telemetry: A Randomized, Controlled Trial - June 15, 2015
- Myocardial Fibrosis on Cardiac Magnetic Resonance and Cardiac Outcomes in Hypertrophic Cardiomyopathy: A Meta-Analysis - June 9, 2015
- Performance of CMR Methods for Differentiating Acute From Chronic MI - June 9, 2015